Koss Olinger Consulting LLC Has $1.06 Million Stake in Bio-Rad Laboratories, Inc. $BIO

Koss Olinger Consulting LLC decreased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 42.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,488 shares of the medical research company’s stock after selling 2,563 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Bio-Rad Laboratories were worth $1,057,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Danske Bank A S acquired a new stake in shares of Bio-Rad Laboratories in the 4th quarter valued at $30,000. Geneos Wealth Management Inc. raised its holdings in Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares during the period. Farther Finance Advisors LLC raised its holdings in Bio-Rad Laboratories by 76.9% in the 4th quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock worth $56,000 after acquiring an additional 80 shares during the period. Financial Management Professionals Inc. bought a new position in shares of Bio-Rad Laboratories during the 4th quarter worth about $61,000. Finally, UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 24.0% during the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock worth $58,000 after purchasing an additional 40 shares during the period. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Trading Down 1.7%

BIO opened at $312.72 on Friday. The firm’s fifty day moving average is $278.57 and its two-hundred day moving average is $292.14. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $343.12. The firm has a market cap of $8.37 billion, a PE ratio of 51.52 and a beta of 1.06.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The company had revenue of $592.10 million for the quarter, compared to the consensus estimate of $589.91 million. During the same period in the prior year, the company earned $2.54 EPS. The firm’s revenue was up 1.1% on a year-over-year basis. Equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BIO. Royal Bank Of Canada initiated coverage on shares of Bio-Rad Laboratories in a research note on Friday, May 15th. They issued an “outperform” rating and a $320.00 target price on the stock. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $375.00 to $300.00 in a research note on Tuesday, April 7th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Wells Fargo & Company reduced their target price on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings lowered shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $303.33.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.